Ensysce Biosciences Inc ENSC

Alternate Symbol(s): ENSCW

Healthcare Biotechnology

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

NDAQ:ENSC - Post by User

Ensysce Biosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Jan 23, 2024 10:00am

91 Views

Post# 35840646

Ensysce Biosciences Announces FDA Breakthrough Therapy Desig

Just In: $ENSC Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR~ FDA acknowledges significant potential impact of MPAR's oral overdose protection ~ SAN DIEGO, CA / ACCESSWIRE / January 23, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug s...ENSC - Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale